A metal ring weighing about 4 grams with no screen is planning to list on the Nasdaq as early as September.
Oura, the 13-year-old Finnish smart ring company, plans to raise up to $3 billion in an IPO at a valuation exceeding $16 billion. The underwriters include top banks such as Goldman Sachs, Morgan Stanley, and JPMorgan. According to Omdia, Oura accounted for about 74% of global smart ring shipments in the first half of 2025, with an even higher share in the US market.
If the listing goes through, it will be the largest IPO in consumer wearables in over a decade, far surpassing Peloton's $8.1 billion in 2019 and Fitbit's $4.1 billion in 2015.
But two things are more noteworthy than the amount raised.
First, existing shareholders are selling a large number of shares. People familiar with the matter told Bloomberg that current investors are expected to sell a significant portion of their stock in the IPO. Oura has raised more than $1.5 billion in cumulative funding, with institutions such as Fidelity, ICONIQ, and Whale Rock waiting for an exit window. The Series D round in late 2024 valued the company at $5.2 billion, and the Series E round in October 2025 jumped to $11 billion — more than doubling paper gains in less than a year. Under DPI pressure, such exits are an inevitable part of the capital cycle, not simply a bearish signal.
Second, its most valuable story is being challenged by class-action lawsuits. In December 2025, three consumers filed a class action over automatic renewals in the US District Court for the Northern District of California (Case No. 3:25-cv-10997), alleging that Oura did not clearly disclose auto-renewal terms and made cancellation difficult. In August 2026, a class action over sleep-tracking accuracy directly targets the product's core value — a fundamental conflict between the hardware technology approach and marketing promises.
13 Years: From Finnish Geeks to a $100B Valuation
In 2013, three Finnish engineers founded Oura in Oulu, near the Arctic Circle. Oulu was once one of Nokia's most important R&D centers; after Nokia's exit, many wireless communications and sensor engineers stayed, forming the technical foundation of Oura.
The founding team's original idea was to turn a ring into a health data monitoring device. The choice of a ring was unconventional: the abundant capillaries on the sides of the fingers provide high-quality photoplethysmography signals, and the comfort level encourages long-term wear.
After the first-generation Oura Ring launched in 2015, it remained a niche product within Silicon Valley's tech enthusiast circles. The real turning point came in 2017, when a New York hedge fund manager invested and took the helm as president, transforming the Finnish hardware company into a global consumer brand.
What followed involved an element of luck: in 2018, Prince Harry was photographed wearing the ring, propelling it into the mainstream overnight; in 2020, the NBA bought more than 2,000 units for player health monitoring, shifting Oura's perception from a 'lifestyle product' to a 'professional device.' Mark Zuckerberg has worn it, and Eileen Gu wore it on the Olympic podium. These celebrity moments cultivated an implicit consumer perception of Oura as a 'professional-grade health tool'—and that perception now sits in subtle tension with the sleep-monitoring lawsuit's central question: whether Oura made medical promises that exceeded what its product can actually deliver.
In 2022, Tom Hale, a professional manager with a software background, became CEO. His core assessment on taking the role was that Oura's real business is software, data and AI, not hardware. The growth curve has since steepened sharply: revenue reached $500 million in 2024, doubled to $1 billion in 2025, and is projected to approach $2 billion in 2026. As of May 2026, Oura's paid membership is expected to surpass 5 million this quarter, a fourfold increase in two years; more than 80% of members renew after their first year.
Based on public financial data, hardware sales currently account for roughly 80% of Oura's revenue, with subscription services contributing about 20%. As of mid-2025, its annual recurring revenue stood at approximately $144 million. The $16 billion overall valuation implies a price-to-sales multiple of about 16 times; but using subscription revenue alone as the denominator, the multiple exceeds 110 times—meaning the capital markets are pricing Oura as a SaaS company, not a hardware maker. Oura is now in the painful transition from a 'hardware company valuation' to a 'SaaS company valuation': if subscription metrics fail to keep improving, the $16 billion valuation could face a 'Davis double-kill'—both earnings and valuation contracting.
‘Almost Like Flipping a Coin’: Core Selling Point Taken to Court
Just as Oura was racing toward an IPO, a lawsuit put its core product logic on trial.
On August 20, 2026, the U.S. District Court for the Northern District of California accepted a proposed class-action lawsuit accusing Oura of deceiving consumers over the accuracy of its sleep-tracking features.
The complaint's central argument is pointed: sleep happens in the brain, not the finger. The medical gold standard is polysomnography, which requires professional equipment such as EEG to measure brain activity. The Oura Ring, worn on the finger, lacks the ability to measure electrical brain activity. The lawsuit cites a study published in Nature finding that Oura's accuracy in distinguishing among awake, light sleep, deep sleep and REM sleep was about 53.18%—described by the plaintiffs as 'roughly equivalent to a coin toss.'
But two key concepts need to be distinguished: Oura's claimed 95% accuracy refers to a binary classification of 'asleep versus awake,' while the 53.18% figure refers to classification accuracy across four sleep stages—entirely different metrics. Consumer wearable devices broadly face technical bottlenecks in sleep-stage accuracy. Oura responded that it cited independent research published in Sensors in October 2024, which found the Oura Ring outperformed the Apple Watch Series 8 in distinguishing light, deep and REM sleep stages. Oura stressed that the product is not a medical device and cannot replace professional sleep testing.
The essence of the dispute is that wearable devices inferring brain sleep states from peripheral signals (heart rate, body temperature, movement) is an industry-wide challenge, not unique to Oura. The core battleground of the litigation is not whether the ring is accurate, but whether Oura's marketing language made medical-accuracy claims beyond the product's actual capabilities — that is the true boundary of the legal dispute.
Beyond product-technology disputes, Oura's hardware-plus-subscription business model itself faces compliance pressure. In December 2025, three consumers filed a class-action lawsuit in the U.S. District Court for the Northern District of California alleging that Oura failed to clearly disclose auto-renewal terms during the purchase process and erected barriers in the cancellation process, potentially violating California's auto-renewal law. The subscription model is the key fulcrum for Oura's valuation shift from a hardware company to a SaaS company, and renewal-compliance issues are precisely what is undermining that fulcrum.
Is AI a Story or a Bubble?
At its Series E round in October 2025, Oura was valued at $11 billion. Less than a year later, its IPO target valuation has risen to $16 billion, an increase of more than 45%. The valuation growth stems from both hardware sales and the AI narrative — in 2024, Oura launched its AI health assistant, Oura Advisor.
But what exactly does Oura Advisor do? Public information so far shows it mainly provides text summaries and trend interpretations based on sleep, HRV, and body-temperature data — not medical diagnosis, but "personalized health insights." This means the AI has not created a new revenue stream; it repackages existing health data. If it is merely natural-language summaries of existing data, it can hardly support the AI premium in the valuation on its own.
The bigger question is the wall of credibility. How much credence will doctors give to the health data Oura can provide? The FDA has warned that the market contains unauthorized smart devices claiming to measure blood pressure and non-invasive glucose. The more important the health issue, the harder it is for consumers to judge on their own.
More worth probing is the structure of the subscription data. Oura has disclosed: "Paid members are expected to surpass 5 million this quarter, quadrupling over the past two years; more than 80% of members renew after the first year." Based on cumulative sales of over 5.5 million rings, the non-subscription rate is about 9%, and the subscription conversion rate is already excellent for consumer hardware. But the future challenge is whether customer-acquisition costs and renewal stickiness will change as the base grows from 5 million to 10 million — that will determine whether the SaaS narrative can hold.
The Window Before Big Tech Moves In
The bigger question: How long can Oura's first-mover advantage last?
Samsung launched a smart ring two years ago, and the Galaxy Ring 2 is already in development. Apple is reportedly developing a smart ring, led by Eddy Cue, senior vice president of services and health — but note that the Apple ring remains an industry rumor, with no official announcement, so its risk weight should be viewed as a medium-to-long-term variable rather than an immediate threat.
Oura's competition extends beyond rumored giants. Fitness-band maker Whoop has seen its valuation soar to $10 billion by moving into areas like hormone tracking. In China, as major players like Dreame enter the market, brands such as RingConn are quickly gaining share with no subscription fees and high cost-performance. In November 2025, Oura filed a Section 337 complaint with the U.S. International Trade Commission (Case No. 337-TA-1468), accusing Samsung, Reebok, Huami, and more than ten other companies of patent infringement, and requesting limited exclusion and cease-and-desist orders. At the same time, Oura itself faces pressure from a Samsung-initiated Section 337 investigation (Case No. 337-TA-1478), in which it is named as a respondent.
In the patent war, Oura is both an aggressor and a target. Domestic competitors are currently focusing on the affordable segment, with limited overlap with Oura's North American premium market above $300. The bigger threat is a longer-term price war.
Oura's other moat is often overlooked: its B2B business. Its partnership with the U.S. Department of Defense dates to 2019 and is currently its largest enterprise customer. The company has also frequently acquired corporate health analytics firms and integrated data with virtual women's health platform Maven Clinic. While this B2B revenue is not separately disclosed, it forms a key pillar of Oura's data-platform narrative.
Behind the $16 billion valuation lie four overlapping risks: class-action lawsuits, delivering on the AI narrative, early shareholders cashing out, and encirclement by tech giants. What Oura needs to prove is not whether smart rings can sell, but whether this niche category can grow into a truly independent, multi-billion-dollar market under pressure from Apple and Samsung.
Two possible scenarios:
Scenario A: Oura goes public successfully, holds its niche in premium health rings, and leverages first-mover advantage and brand mindshare to become a small but profitable independent brand with high pricing power.
Scenario B: After Apple and Samsung enter, the category becomes fiercely competitive, health-data moats are eroded by ecosystem advantages, and independent players are squeezed out. The $3 billion raise only buys a little time before the giants fully arrive.
The Oura IPO is, at its core, an eternal question for the consumer health sector: how close can data from peripheral sensors get to medical truth? The answer Oura provides will also define the valuation ceiling and narrative boundaries for a wave of health-hardware companies to follow. The price of both scenarios is already embedded in the $16 billion valuation.